Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses
| العنوان: | Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses |
|---|---|
| المؤلفون: | Raj S. Kasthuri, Silvio Antoniak, Nigel S. Key, Nigel Mackman, Alisa S. Wolberg |
| المصدر: | Arteriosclerosis, Thrombosis, and Vascular Biology |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Pneumonia, Viral, coronavirus, pandemics, 030204 cardiovascular system & hematology, medicine.disease_cause, Fibrin, Betacoronavirus, 03 medical and health sciences, 0302 clinical medicine, Brief Reviews, medicine, Humans, fibrin, Platelet activation, Respiratory system, Blood Coagulation, Coronavirus, Respiratory tract infections, biology, SARS-CoV-2, business.industry, COVID-19, Thrombosis, Neutrophil extracellular traps, Blood Coagulation Disorders, medicine.disease, orthomyxoviridae, 030104 developmental biology, Viral pneumonia, Immunology, biology.protein, Coronavirus Infections, Cardiology and Cardiovascular Medicine, business |
| الوصف: | The world is amid a pandemic caused by severe acute respiratory syndrome-coronavirus 2. Severe acute respiratory syndrome-coronavirus causes serious respiratory tract infections that can lead to viral pneumonia, acute respiratory distress syndrome, and death. Some patients with coronavirus disease 2019 (COVID-19) have an activated coagulation system characterized by elevated plasma levels of d -dimer—a biomarker of fibrin degradation. Importantly, high levels of D -dimer on hospital admission are associated with increased risk of mortality. Venous thromboembolism is more common than arterial thromboembolism in hospitalized COVID-19 patients. Pulmonary thrombosis and microvascular thrombosis are observed in autopsy studies, and this may contribute to the severe hypoxia observed in COVID-19 patients. It is likely that multiple systems contribute to thrombosis in COVID-19 patients, such as activation of coagulation, platelet activation, hypofibrinolysis, endothelial cell dysfunction, inflammation, neutrophil extracellular traps, and complement. Targeting these different pathways may reduce thrombosis and improve lung function in COVID-19 patients. |
| تدمد: | 1524-4636 1079-5642 |
| DOI: | 10.1161/atvbaha.120.314514 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3253a0e7bfb76aa108935414f29fc015 https://doi.org/10.1161/atvbaha.120.314514 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3253a0e7bfb76aa108935414f29fc015 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15244636 10795642 |
|---|---|
| DOI: | 10.1161/atvbaha.120.314514 |